PubMed HealthSearch

Biomedical subjects

B Jandrig

Publications and source records attributed to B Jandrig.

17 recordsLinked to original sources

Mammalian protein homologous to VAT-1 of Torpedo californica: isolation from Ehrlich ascites tumor cells, biochemical characterization, and organization of its gene.

Recently, interest has focused on the human gene encoding the putative protein homologous to VAT-1, the major protein of the synaptic vesicles of the electric organ of the Pacific electric ray Torpedo californica, after it has been localized on chromosome locus 17q21 in a region encompassing the breast cancer gene BRCA1. Chromosomal instability in this region is implicated in inherited predisposition for breast and ovarian cancer. Here we describe isolation and biochemical characterization of a mammalian 48 kDa protein homologous to the VAT-1 protein of Torpedo californica. This VAT-1 homolog was isolated from a murine breast cancer cell line (Ehrlich ascites tumor) and identified by sequencing of cleavage peptides. The isolated VAT-1 homolog protein displays an ATPase activity and exists in two isoforms with isoelectric points of 5.7 and 5.8. cDNA was prepared from Ehrlich ascites tumor cells, and the murine VAT-1 homolog sequence was amplified by polymerase chain reaction and partially sequenced. The known part of the murine and the human translated sequences share 97% identity. By Northern blots, the size of the VAT-1 homolog mRNA in both murine and human (T47D) breast cancer cells was determined to be 2.8 kb. Based on the presented data, a modified gene structure of the human VAT-1 homolog with an extended exon 1 is proposed. VAT-1 and the mammalian VAT-1 homolog form a subgroup within the protein superfamily of medium-chain dehydrogenases/reductases.

Adenosine Triphosphatases

Generation of lymphoma-type variant hamster polyomavirus genomes in hamsters susceptible to lymphoma induction.

The hamster polyomavirus (HaPV) induces either hair follicle epitheliomas or lymphomas in either Z3 or HaP respectively. Syrian hamsters. In the lymphomas specifically deleted "lymphoma-type" (lt) HaPV genomes are accumulated. In the present study the temporal pattern of generation of HaPV (lt) DNA was investigated in context of the development of lymphomas in neonatally infected HaP hamsters. The generation of HaPV (lt) DNA was first detectable during the postnatal phase of high level replication of viral DNA in hemopoietic organs (at 7 days post infection), thus clearly preceding the development of overt lymphoma. A variety of HaPV (lt) DNA species is generated in lymphoid cells, but usually only one of them is accumulated to high amounts in lymphoma cells. Furthermore, the pattern of HaPV (lt) and wild-type (wt) DNA was studied in normal and tumor tissues of tumor-bearing hamsters as well as in tumor-free hamsters. In tumor-bearing hamsters predominantly HaPV (lt) DNA species were found in the infected tissues, while HaPV (wt) DNA was detected rarely and only in tumor-free tissues. In contrast, in tissues of tumor-free hamsters HaPV (wt) DNA prevailed over HaPV (lt) DNA species.

Animals

Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis.

We have identified a high frequency of loss of heterozygosity (LOH) on the human chromosome region 8p12-p22 in a panel of microdissected familial (86% LOH) and sporadic (74% LOH) breast tumours. The two most frequently deleted regions were defined around marker D8S133 and in a broader centromeric region bounded by markers D8S137 and D8S339. We cannot unequivocally characterize the 8p12-p22 loss as an early or a late event in breast carcinogenesis. In parallel, we have performed linkage analysis in four German breast cancer families. A location score greater than 13.67 corresponding to a LOD score of 2.97 at the marker D8S137 has been obtained. Our results considerably strengthen the evidence for a breast cancer susceptibility gene(s) located on the short arm of the chromosome region at 8p12-p22.

Adult

Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer.

Several clinical and experimental investigations suggest that the action of antineoplastic chemotherapy in premenopausal women influences the menopause. Such hormonal reactions are mediated via specific steroid hormone receptors. Therefore, connections between hormone receptors and antineoplastic chemotherapy can be assumed making possible to predict success of chemotherapy on the basis of receptor status. Nevertheless, clinical experiences and animal and cell culture experiments yielded controversial results. This was related to the predictive value of receptor status as well as to the benefits of combined hormone and chemotherapy treatments in concurrent or sequential form. It is undeniable that a displacing of steroidal ligand from its receptors by the usual antineoplastic drugs does not occur. Furthermore, the receptor levels remain unchanged after a treatment with antineoplastic drugs. Thus, the mechanism of action of chemotherapeutic drugs is not related directly to the presence or absence of steroid hormone receptors. Despite this fact the receptor status in chemotherapeutic regimes seems to be helpful to define low or high risk patients. Influences on the ER de-novo-synthesis, actions related to parameters representing reduced tumor growth rates, down-regulation of the receptor gene expression or via receptor mediated hormonal actions to other genes, like the apoptosis-related gene bcl-2, are thought to be possible mechanisms of action of antineoplastic drugs on steroid hormone receptors. Future investigations should monitor the ratios between exon lacking receptor variants and the wild-type receptor during chemotherapy or the control of a ligand uptake during chemotherapy by means of the positron emission tomography.

Antineoplastic Agents, Hormonal

BRCA1 mutations in German breast-cancer families.

We analyzed germline mutations of the BRCA1 gene in 20 German breast/ovarian-cancer families. BRCA1 mutations co-segregating with breast-cancer susceptibility were identified in 3 of these families. All mutations were found to generate a premature stop codon leading to the synthesis of truncated BRCA1 proteins of different length. Nine polymorphisms were detected in BRCA1, 4 of which have not been described previously. Analysis of familial tumors for LOH revealed that only the disease-related allele of BRCA1 was present.

Adult

A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer.

Recent evidence obtained by cytogenetic and molecular studies indicates that in breast cancer chromosome 6q is often affected by genetic changes suggesting the existence of putative tumor suppressor genes (TSGs). However the function of gene(s) on this chromosome in breast cancer suppression is not understood. To substantiate further the presence of breast cancer related TSGs at 6q and to define their location, we first performed microcell-mediated transfer of chromosome 6 to CAL51 breast cancer cells for studying possible suppression of malignant phenotype and secondly, we analysed DNAs from 46 primary breast cancers for loss of constitutive heterozygosity (LOH) using 24 poly-morphic microsatellite markers. The chromosome transfer resulted in loss of tumorigenicity and reversion of other neoplastic properties of the microcell hybrids. Polymorphism analysis of single hybrids revealed that they harbored only a small donor chromosome fragment defined by the marker D6S310 (6q23.3-q25) and flanked by D6S292 and D6S311. The LOH data suggest that four tumor suppressor gene loci mapped to the central and distal portion of 6q may be independently deleted in breast cancer. One of these regions corresponds to the region identified by chromosome transfer.

Breast Neoplasms

Genomic structure and chromosomal localization of the human interleukin 15 gene (IL-15).

Interleukin 15 (IL-15) is a novel cytokine whose biological activities are similar to those of interleukin 2 (IL-2). The genomic sequence of human IL-15 has been isolated based on its sequence homology with a cDNA clone encoding human IL-15. The human sequence is 14968 bp in length and includes all six protein-coding exons and five introns. The location of the introns in the human sequence is identical to their positions in the murine IL-15 gene. The same is true for the overall size of the gene, which was estimated to be at least 32 kb. Using Polymerase Chain Reaction (PCR) with gene-specific primers on a panel of human/rodent hybrid cell DNAs, as well as by fluorescence in situ hybridization the human IL-15 gene was mapped to chromosome 4 region q25-35.

Amino Acid Sequence

BRCA1 mutation update and analysis.

The discovery of the BRCA1 gene involved in the development of human hereditary breast cancer led to extensive international efforts to identify the mutations leading to the disease. The new listing covers 127 mutations published in the indicated papers before 30 April 1996; 55% of the mutations are localized in exon 11, followed by exons 2 (5.5%), 5 and 16 (4.7% each).

Exons

Estradiol receptors and metastasis in human breast cancer.

The localization and extent of metastasis determined the prognosis of breast cancer in a decisive manner. Thereby axillary lymph node involvement represents one of the most important prognostic indicators. The estradiol receptor status is also attributed some prognostic importance. There might therefore be relations between these prognostic factors. However, the majority of investigators could not find a correlation between the extent and timing of regional lymph node involvement and estradiol receptor status. In contrast, there are numerous findings which confirm correlations between estradiol receptors and the localization, extent, and timing of distant metastasis. The findings obtained in more recent years have been collected and discussed in relation to events included in the process of metastasis such as release of proteases and existence of receptor variants.

Breast Neoplasms

Membrane transport in multidrug resistance, development, and disease. AACR special conference in cancer research.

The main goal of this meeting was to provide the scientists and clinicians active in this field with a comprehensive overview of the progress that has been made. The meeting was a forum in which new advances in membrane transport were discussed in depth and which gave new impulses for clinical applied research. Again, the importance of intensive cooperation between basic research and clinical use became evident during this symposium.

Animals

Amplification of oncogenes and disease prognosis.

Amplification is one mechanism for activation of oncogenes and results in an excess of DNA template, which can lead to overproduction of oncogene-specific RNA and protein. Amplification of oncogenes has been observed in different tumor tissues. In certain cases amplification and overexpression of particular oncogenes have been correlated with tumor progression and clinical behavior. The best example is neuroblastoma in which the N-myc oncogene frequently is found to be amplified. Over 1,000 patients with breast cancer have been studied for amplification of the c-erbB-2 oncogene until now. The evidence from the studies that amplification of c-erbB-2 is correlated with poor prognosis is in our opinion not convincing. More and more investigations about oncogenes and disease prognosis will take place rather at the protein level than at the DNA level.

Gene Amplification

In vitro transformation of rat cells by 3-methylcholanthrene: activation of the ras oncogene.

Rat cells of the established, immortalized line rat-2 were treated with the polycyclic aromatic hydrocarbon 3-methylcholanthrene. No characteristic morphological transformation occurred during three weeks after treatment. However, the carcinogen-treated cells formed colonies in soft agar. Cell lines established from single soft agar colonies were characterized by an increased proliferation rate, an enhanced colony formation in soft agar and an increased expression of the Ha-ras oncogene.

Animals

Activated fos oncogene in rat embryo fibroblasts transformed by ras and myc oncogenes.

Rat embryo fibroblasts (REF) were transformed by simultaneous gene transfer of the complementary oncogenes ras and myc using the calcium phosphate coprecipitation method. Cell lines derived from transformation foci expressed in addition to ras and myc cellular oncogene fos while normal REF did not express ras, myc and fos according to the hybridization methods used. The transformed cell lines produced colonies in soft agar and tumors in newborn syngeneic rats. From one tumor a cell line was established which was characterized by a high level of fos gene expression.

Animals

Transformation of rodent immortalized and embryo cells by oncogenes. I. Mouse (NIH 3T3) and rat (FR 3T3) immortalized fibroblasts.

Immortalized mouse NIH 3T3 cells were transformed by gene transfer of DNA isolated from a human bladder tumor cell line and plasmids containing an activated human Ha-ras oncogene insert. For gene transfer the calcium-phosphate co-precipitation method was used. Transformation was evaluated by morphological focus formation, growth in soft agar and tumor development in nude mice. In addition, immortalized rat FR 3T3 cells were transformed by Ha-ras, too. The co-transfer of ras and myc oncogenes did not enhance focus formation in FR 3T3 cells.

Animals

Transformation of rodent immortalized and embryo cells by oncogenes. II. Rat embryo fibroblasts (REF).

Rat embryo fibroblasts were transformed by co-transfer of two plasmids carrying the oncogenes ras and myc, respectively. In contrast to immortalized cells gene transfer of ras alone was not sufficient for transformation of rat embryo cells. Embryo cells transformed by both oncogenes showed an altered morphology and produced colonies in soft agar. Cell lines were established from transformation foci. These cells are characterized by a high proliferation capacity, they expressed the oncogenes ras and myc and produced regressing tumors in syngeneic newborn rats. Oncogene expression was demonstrated by in situ and blot hybridization. A cell line was established from a rat tumor induced by oncogene transformed cells. This cell line, designated FTD5, showed in addition to an increased expression of the transferred oncogenes ras and myc an elevated expression of the cellular oncogene fos.

Animals

Steroid hormone receptors related to parameters characterizing the biology of human breast cancer.

Steroid hormone receptors are important parameters to characterize breast tumors. Thus, it is important to evaluate their relationships with factors such as histological type and size of the tumor, axillary lymph node invasion and distant spread, age and menopausal status of the patients, and parameters of tumor differentiation. The receptor levels observed vary within wide ranges. Therefore, statistically significant differences between different groups of parameters are seldom found. A significant dependence on receptor levels has been observed only for patient age and menopausal status. The parameters clinical stage, tumor size, tumor histology, metastatic involvement and histopathologic grading showed no statistically significant relation with receptor levels. Nevertheless, a relationship exists between all parameters mentioned and the frequency of a positive receptor status. Consequently, receptor status can contribute to define the biological behavior of the disease in specific groups of patients. In individual cases other parameters than the biochemical evidence of steroid receptor binding seem to be more important. We found that data derived from DNA flow cytometric measurements allowed a better recognition of tumor aggressiveness than ER status. In axillary lymph node metastases we usually observed higher receptor levels than in primary tumors, but we did not find an age dependency of ER levels in these metastases.

Adult